Express News | NYSE Order Imbalance 295733.0 Shares on Buy Side
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
The Stock Market Is Looking Vulnerable. It Could Be the Start of a Summer Slump.
It's hard to ignore this past week's wild swings, one that even Nvidia's strong earnings couldn't prevent. "The risk for stocks is to the downside," says one strategist.
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Thursday, Verastem Oncology (NASDAQ:VSTM) announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination wit
Global Diabetes Drug Analysis Report 2024: A $107.02 Billion Market by 2032 Driven by Novo Nordisk, AstraZeneca, Biocon, Sanofi, Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Novartis
Express News | Bristol Myers Squibb To Present Data Across Its Oncology And Hematology Portfolio At Upcoming ASCO Annual Meeting And EHA Hybrid Congress
Unusual Options Activity: MTDR, NSC and Others Attract Market Bets, MTDR V/OI Ratio Reaches 138.9
EST May 23rd Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
Express News | NYSE Order Imbalance 562212.0 Shares on Buy Side
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 18.82% since its last report. The company recently reported that it has 28.02 million shares sold short, which is 1.38% of all regul
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974 ("ERISA") (Brower Piven Release)
BALTIMORE, May 23, 2024 (GLOBE NEWSWIRE) -- Lawsuits have been filed alleging that a number of large corporate employers have offloaded billions of dollars in pension obligations to Athene Annuity and Life Company
Does Bristol-Myers Squibb (NYSE:BMY) Have A Healthy Balance Sheet?
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment
Bristol-Myers Squibb (BMY) said Thursday that additional data from the EMERGENT-5 trial supports KarXT's potential as a unique schizophrenia treatment. The long-term trials, consistent with short-term
Express News | Bristol Myers Squibb To Present KarXT Data At ASCP May 28-31
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
Bristol-Myers Squibb Options Spot-On: On May 22nd, 68,057 Contracts Were Traded, With 658.5K Open Interest
On May 22nd ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 68,057 options for the day, of which put options accounted for 58.6% of the total transactions
Bristol-Myers Squibb Snaps Six Days of Losses, Trades in the Green
Bristol-Myers Squibb (NYSE:BMY) shares traded in the green on Tuesday, breaking six straight days of losses.
Express News | NYSE Order Imbalance 482454.0 Shares on Sell Side
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Bristol Myers Squibb BMY announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation of Opdivo (nivolumab) on Dec 29, 2024.
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines
Bristol-Myers Squibb (BMY) said Wednesday it has drawn up a 10-year strategy to expand patient access to its medicines in low- and middle-income countries. Under the 10-year program, Bristol-Myers sai
Express News | Bristol Myers Squibb Announced Aspire, A 10-year Strategy With An Aim To Reach Over 200,000 Patients In Low-And Middle-Income Countries By 2033, As Part Of Aspire, Bristol Myers Is Developing Tailored Strategies To Increase Affordability And Availability
No Data